NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- Prolium Bioscience, Inc. (Prolium), a clinical stage biotechnology company, today announced that the first patient has been dosed in a multinational, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results